(Q59530426)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

main subject

phase II clinical trial

1 reference

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Giuseppe Di Lorenzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Mario Giuliano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Emilio Morelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Giorgio Napodano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Aniello Russo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Giuseppe Benincasa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Vincenzo Altieri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sabino De Placido

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Riccardo Autorino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Massimino D'Armiento

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

347-351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Hormone-refractory (D3) prostate cancer: refining the concept.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Satraplatin in the treatment of hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

Future directions in the treatment of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.007

10.1016/J.UROLOGY.2006.10.007

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17320676%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference